Nurhayati Mohd Marzuki Malaysia

Dr. Nurhayati binti Mohd Marzuki MBBCH BAO LRCP&SI, MMed (Int Med), Fellowship in Respiratory Medicine, CMIA Dr. Nurhayati binti Mohd Marzuki serves as the Director of the Institut Perubatan Respiratori (IPR) and Deputy Head of the Ministry of Health Malaysia’s Respiratory Medicine Subspecialty Service. A Consultant Respiratory Physician with over 17 years of specialist experience, her clinical and research interests include thoracic oncology and tobacco control. In the field of tobacco control, she has coordinated IPR’s Smoking Cessation Services since 2012 and chaired the development of Malaysia’s Clinical Practice Guidelines for EVALI. Her expertise is frequently utilized in national policy development, including technical committees for e-cigarette regulation and legislative briefings. Dr. Nurhayati is also an active researcher, having served as a Principal Investigator for international trials on chronic cough and lung cancer genomics. Beyond her clinical and administrative duties, she is a Trustee for Lung Foundation Malaysia.
Job Title
Director and Consultant Respiratory Physician
Faculty / Department / Division
Respiratory Medicine
Institution / Organisation
Institute of Respiratory Medicine

19 November 2026, Thursday

Time Session
08:30
13:20
Henry Marshall Chairperson Australia
Nurhayati Mohd Marzuki Chairperson Malaysia
  • Henry Marshall Speaker Australia
    Nurhayati Mohd Marzuki Speaker Malaysia
  • Siti Munira Yasin Speaker Malaysia
    The increasing use of electronic cigarettes and heated tobacco products has raised concerns about their potential health effects, particularly among younger populations. This presentation explores the evolution of nicotine delivery devices and how differences in device design, chemical composition and heating mechanisms influence toxicant exposure. Although electronic cigarettes and heated tobacco products may produce lower levels of certain harmful chemicals compared to conventional cigarettes, they still expose users to nicotine, reactive carbonyls, metals and other potentially harmful substances. The presentation discusses how these chemicals contribute to oxidative stress, inflammation, respiratory injury and cardiovascular effects. Emerging nicotine analogues and changing patterns of product use pose further challenges in understanding their long-term health consequences. Particular attention is given to the Malaysian context, including dual use, smoking cessation and regulatory challenges. Understanding these differences is essential for clinicians to communicate health risks effectively, support informed decision-making and promote evidence-based tobacco cessation strategies. Keywords: Electronic cigarettes, heated tobacco, toxicology, nicotine, respiratory health.
  • Amer Siddiq Amer Nordin Speaker Malaysia
    Smoking cessation is a key component of respiratory care, yet effective counselling must address differences in readiness to quit, personal beliefs and sociocultural context. This presentation examines practical behavioural interventions that pulmonologists can integrate into routine clinical encounters with culturally diverse Asia-Pacific populations. Using clinical scenarios, the session explores brief advice through the 5As and 5Rs, motivational interviewing using open-ended questions, affirmations, reflective listening and summarising, and cognitive behavioural strategies for managing cravings, challenging unhelpful beliefs and preventing relapse. The stages-of-change framework provides a practical approach to understanding readiness and tailoring conversations to patients’ needs. Cultural adaptation is considered through patients’ language preferences, health beliefs, family relationships and social norms surrounding tobacco use. Emphasis is placed on respectful, collaborative communication that elicits patients’ own reasons for quitting and supports achievable behavioural goals. Participants will gain practical approaches to initiating cessation conversations, addressing ambivalence and responding constructively to lapses. Integrating these approaches with appropriate pharmacotherapy and follow-up offers pulmonologists a comprehensive framework for supporting sustained smoking cessation across diverse clinical settings.
  • Suthat Rungruanghiranya Speaker Thailand
    "Tobacco dependence remains the leading single cause of preventable global morbidity and mortality, accounting for over 7 million deaths annually among 1.3 billion tobacco users worldwide. An acute global equity gap persists: 80% of all tobacco users reside in Low- and Middle-Income Countries (LMICs), yet population-level access to World Health Organization (WHO) best-practice cessation services stands at only 4% in low-income countries and 11% in middle-income countries, compared to 28% in high- income countries (HICs). While HIC treatment guidelines rely heavily on insurance-covered, high-cost first-line pharmacotherapies such as Varenicline ($400–$500 per course) and combination nicotine replacement therapy (NRT), LMIC populations face a severe economic hurdle where the out-of-pocket cost for a single month of NRT frequently exceeds the cost of continuing to smoke. This presentation evaluates strategies to bridge this global divide by analyzing the neurobiological imperatives of tobacco addiction, comparing clinical treatment guidelines, and introducing high-efficacy, low-cost pharmacotherapy combined with scalable community delivery models. Neurobiological evidence confirms that tobacco dependence is a physiological receptor-driven addiction requiring pharmacotherapy, which quintuples cessation success compared to unassisted quit attempts (~25% vs ~5%). Cytisine—a plant-based partial α4β2 nicotinic receptor agonist costing ~$20–$30 per treatment course—emerges as a transformative solution for LMICs. Clinical evidence from the randomized, double-blind Thai STEP trial (Respirology 2024; n=1,086) demonstrated that a 25-day course of locally manufactured Cytisine achieved non-inferior continuous abstinence rates compared to a 12-week course of Nortriptyline (10% at 12 months) with favorable tolerability. To operationalize these findings in resource-constrained health systems, a three-tiered LMIC master-algorithm is presented: task-shifting initial screening (Ask & Advise) to Community Health Workers, scaling automated mobile mCessation behavioral support, and providing generic Cytisine. Because global tobacco control 's primary challenge is structural rather than scientific, pairing affordable essential medicines with community-based participatory care offers a proven, equitable path toward reducing global tobacco mortality."
  • Coral Gartner Speaker Australia
    This workshop will discuss the harm minimisation framework of the three pillars of demand, supply and harm reduction as it applies to tobacco and nicotine products. The tobacco industry’s misuse of the ‘harm reduction’ concept and industry promotion of e-cigarettes and other non-therapeutic nicotine products will be explored. Participants will think through how the harm reduction concept of safer supply might be applied to tobacco and nicotine products. The Australian Pharmacy-only model for e-cigarette supply will be discussed as a real-world pragmatic example of a supply model that is consistent with a harm minimisation framework, in contrast with the industry’s preferred model of general retail supply via a ‘consumer product’ model.
  • Ser Hon Puah Speaker Singapore
  • Coral Gartner Speaker Australia
    Both health and non-health related workplaces and community settings can be engaged to deliver cost-effective smoking cessation interventions and to encourage adoption of smokefree workplaces and homes. The presentation will discuss the case study of the 10,000 Lives regional program that recruited champions from multiple organisations within the Central Queensland Hospital and Health Service Area. The initiative focused on increasing uptake of existing programs, including delivery of brief interventions, referral to the Quitline and promoting adherence to smokefree laws. Participants will be encouraged to consider a wide range of community and workplace partners who could be potential partners.
  • Suthat Rungruanghiranya Speaker Thailand
    Tobacco use remains the leading preventable cause of death across the Asia-Pacific region, yet this area also demonstrates that comprehensive, well-financed, and industry-insulated legislation can effectively reduce smoking prevalence. This summary explores the legislative and governance frameworks essential for robust tobacco control, primarily focusing on the WHO Framework Convention on Tobacco Control (FCTC) and the MPOWER technical package. Effective governmental strategies require simultaneous implementation of multiple measures, including progressive excise taxation, comprehensive smoke-free laws, and standardized packaging with pictorial health warnings. Furthermore, securing earmarked and transparent financing, as exemplified by Thailand's Health Promotion Foundation (ThaiHealth), provides the operational continuity necessary to sustain long-term public health campaigns. A persistent challenge in the region is tobacco industry interference, which necessitates strict adherence to FCTC Article 5.3 to protect public health policies from commercial vested interests. Thailand’s ongoing four-decade confrontation with the tobacco industry and New Zealand’s recent reversal of its ambitious "endgame" legislative package illustrate that even rigorous, evidence-based policies remain politically fragile without durable cross-party consensus and strict firewalls. Furthermore, novel nicotine products, such as e-cigarettes and heated tobacco, are increasingly utilized by the industry to access policymaking processes under the guise of harm reduction. To ensure durable population-level reductions in tobacco use, the following structural features are recommended: (1) Implement the full MPOWER package simultaneously rather than relying on isolated measures. (2) Establish earmarked, transparent financing insulated from annual budget politics. (3) Enact and continuously monitor strict Article 5.3 firewalls across all government branches, including regulations for novel nicotine products. (4) Invest in sustained tobacco industry denormalization (TID) to educate the public and policymakers about industry tactics. (5) Foster regional technical and diplomatic solidarity to support smaller nations in translating FCTC obligations into enforceable laws.
  • Nurhayati Mohd Marzuki Speaker Malaysia
    “Systems Thinking” in Cessation: Situating Cessation as an Integral Service Within Primary Care and Pulmonary Medicine Nurhayati Mohd Marzuki, Institut Perubatan Respiratori, Kuala Lumpur, Malaysia Background: Smoking cessation is among the most effective treatments in respiratory medicine, yet it is rarely delivered as a routine service. In Malaysia, 85% of smokers intend to quit, and primary care doctors ask and advise almost every smoker, but only half arrange follow-up. We describe a systems approach to cessation at a tertiary respiratory centre, Institut Perubatan Respiratori (IPR), Kuala Lumpur. Methods: We framed cessation as a system with four parts: identification, treatment at first contact, continuation after discharge, and feedback of outcomes. Smoking status was built into the admission nursing assessment. Staff of all ranks were trained as Certified Smoking Cessation Service Providers (CSCSP). Nurses and pharmacists identify, advise and counsel; doctors prescribe nicotine replacement therapy (NRT) on the ward. After discharge, patients continue at IPR's daily Quit Smoking Clinic (Klinik Berhenti Merokok, KBM) or at a cessation centre nearer home. We reviewed service data from 2020 to 2025. Results: Eighty-one staff across seven cadres are CSCSP-certified. Annual KBM patients rose from 119 in 2020 to 233 in 2025. The 6-month carbon monoxide-verified quit rate among clinic attenders rose from 11.9% in the first half of 2023 to 29.2% in the second half of 2025. In 2025, 211 inpatients started NRT on the ward and 102 were referred to KBM. Outcomes for the remaining patients, who continued elsewhere or defaulted, are not captured. Conclusion: A ward-initiated, whole-team model was associated with greater cessation activity and higher quit rates at a Malaysian respiratory centre. The missing component is feedback on patients referred out. Cochrane evidence shows that support continuing beyond one month after discharge increases quitting (RR 1.36). We therefore propose a shared referral and outcome register, intention-to-treat reporting, and a named primary care partner to close the loop.
  • Ser Hon Puah Speaker Singapore
  • Henry Marshall Speaker Australia
    Nurhayati Mohd Marzuki Speaker Malaysia
Function Room 7, Ground Mezzanine Floor

21 November 2026, Saturday

Time Session
09:30
10:30
Tan Jiunn Liang Chairperson Malaysia
Yasutaka Nakano Chairperson Japan
  • Asiah Kassim Speaker Malaysia
    Both Technical Standards of Spirometry and Lung Volume by ATS/ERS in 2019 and 2023 highlighted the importance of the equipment, quality assurance of the equipment and training of operator handling the equipment and the test. The technique of spirometry prefers both expiratory and inspiratory, calculation of BEV, acceptability of FEV1 and FVC and not the maneuver, repeatability and quality spirometry and lung volume values. The changes require more trained operator and time for the test to be done with a new equipment for measurement. The clinical application of the usable FEV1 and FVC values for interpretation is helpful in certain group of patients like children. However, the new definition of bronchodilator responsiveness based on predictive value is not adapted by GINA or GOLD 2026 as both definitions in 2005 and 2022 is still comparable.
  • Susumu Sato Speaker Japan
    "Beyond Spirometry: Integrating Morphometry and Mechanics for Precision Medicine Although spirometry remains fundamental to respiratory assessment, conventional indices alone do not fully account for the substantial heterogeneity observed in chronic respiratory diseases. Patients with comparable airflow limitation may exhibit marked differences in symptoms, gas exchange impairment, functional capacity, prognosis, and treatment response. This underscores the need to incorporate additional morphological and physiological dimensions into disease assessment. Flow–volume curves contain valuable yet underutilized information beyond FEV₁ and FEV₁/FVC, including mid- and late-expiratory flows, inspiratory–expiratory relationships, and curve-shape or area-based metrics. When interpreted with careful attention to effort dependence, volume dependence, and technical quality, these features may provide further insight into underlying disease mechanisms. Recent developments in imaging-based morphometry have broadened phenotyping beyond the traditional assessment of emphysema severity. Previous research demonstrated that computed tomography (CT)-derived airway wall dimensions and emphysema provide complementary information regarding pulmonary function, supporting the view that airway and parenchymal abnormalities represent distinct yet interacting contributors to airflow limitation. More recent studies suggest that different CT phenotypes carry distinct clinical implications, with differential associations with longitudinal decline in FEV1 and diffusing capacity, as well as prognosis. In addition, airway structural abnormalities, including airway wall thickening and mucus plugging, may be linked not only to airflow limitation and adverse outcomes, but also to specific disease backgrounds such as a history of asthma. Moreover, the scope of imaging-based morphometry may extend beyond the airways and parenchyma to include extrapulmonary and vascular features, such as muscle dysfunction, thereby providing additional functional and prognostic insights. These findings support an integrated framework in which respiratory disease is understood through the interplay between structural abnormalities and their mechanical consequences. In this presentation, I will discuss how integrating imaging-based morphometry with spirometry and broader physiological assessment may move respiratory medicine beyond a spirometry-centered paradigm toward more precise phenotyping, improved risk stratification, and individualized patient care. "
  • Nguyen Van Tho Speaker Vietnam
    Accurate interpretation of lung function is very important for managing respiratory diseases. Diagnosis and classification of the severity of abnormal lung function tests depend on the reference equations used. The Global Lung Function Initiative (GLI) 2021 reference equations were derived from a large representative sample across the entire age range and different ethnic groups using updated standardized techniques of lung function measurements. However, for the Asia-Pacific region—characterized by immensly different genetic, race, environmental, lifespan and varying healthcare infrastructures—using GLI 2021 reference equations presents diagnostic challenges. Implementation of GLI 2021 in Asian populations requires careful validation against existing "Asian-specific" norms. Research indicates that the application of universal equations can alter the "Lower Limit of Normal" (LLN), potentially impacting the diagnosis of restrictive or obstructive patterns or the impairement of lung diffusion capacity in airways and interstitial lung diseases. The GLI 2021 do not include individual data from all populations in the Asia-Pacific region and do not explicitly consider the factors that may contribute to the observed differences in lung function between populations. GLI DLCO equations and GLI static lung volumes are currently based on measurements predominantly from individuals of European ancestry due to insufficient reference data from other populations. In addition, some institutions in the Asia-Pacific region continue using the old models of lung function tests, which are not suitable for GLI 2021. This presentation will highlight some challenges and potential pitfalls when implementing GLI 2021 in the diverse Asia-Pacific region.
  • Q&A
Ballroom 1, Lower Ground Floor
11:00
12:30
Nurhayati Mohd Marzuki Chairperson Malaysia
  • Keiji Fujiwara Presenter Japan
  • Tomonori Sato Presenter Japan
  • Toshitaka Shomura Presenter Japan
    【Background and Aims】 Bendopnea, defined as dyspnea while bending forward, has been primarily studied in heart failure, but its significance in chronic obstructive pulmonary disease (COPD) remains unclear. Airway mucus plugging, quantified by computed tomography (CT), has emerged as an important imaging marker linked to airflow limitation and symptom burden in COPD. We hypothesized that a higher CT-based mucus plug score is independently associated with the presence of bendopnea in COPD patients. 【Methods】 We conducted a retrospective cross-sectional study of 133 patients with COPD. Bendopnea was assessed clinically and was present in 27 patients (20.3%). Mucus plug score was quantified from chest CT images. Patient demographics, pulmonary function tests, low attenuation volume percentage (LAV%), hemodynamic parameters (BNP, TRPG, EF), and symptom scores were compared between groups. Multivariate logistic regression analyses were performed to evaluate the independent association of mucus plug score with bendopnea, adjusting for %FEV1 and LAV%. 【Results】 Bendopnea-positive group exhibited significantly higher mucus plug scores compared to the Bendopnea-negative group (median 2.0 [IQR 1.0–4.0] vs. 0.0 [0.0–1.0], p < 0.001). The Bendopnea-positive group also demonstrated more severe airflow limitation (%FEV1: 51.3% vs. 73.7%, p < 0.001), greater emphysema (LAV%: 12.2% vs. 3.6%, p = 0.008). In contrast, hemodynamic parameters showed no significant between-group differences. In multivariate logistic regression analyses, mucus plug score remained a significant independent predictor of bendopnea across all models: adjusted for %FEV1, adjusted for LAV%, adjusted for both %FEV1 and LAV%. Bendopnea prevalence increased with rising mucus plug scores (P for trend < 0.001). 【Conclusions】 CT-based mucus plug score is significantly and independently associated with bendopnea in COPD patients, irrespective of the degree of airflow limitation, emphysema. These findings suggest that bendopnea may be a clinical clue to mucus-predominant airway disease in COPD.
  • Shih-Yu Chen Presenter Taiwan
    Background The prognostic value of body mass index (BMI) in chronic obstructive pulmonary disease (COPD) remains inconsistent. The clinical implications of phenotyping based on adiposity and muscularity have not been well established. Methods In this prospective multicenter cohort study, patients with spirometry-confirmed COPD (October 2021–December 2023) underwent bioelectrical impedance analysis. Low fat-free mass index (FFMI) was defined as <17.4 kg/m² (men) and <15.0 kg/m² (women); high fat mass index (FMI) as ≥5.9 kg/m² (men) and ≥7.0 kg/m² (women). Participants were classified into four phenotypes: lean-robust (low FMI, high FFMI), wasting (low FMI, low FFMI), sarcopenic obesity (high FMI, low FFMI), and obese-robust (high FMI, high FFMI). The primary outcome was severe acute exacerbation; the secondary outcome was three-year all-cause mortality. Cox proportional hazards models were applied. Results Among 648 participants (mean age 73.2 years; 88.6% male), 6.9% were underweight, 29.9% overweight and 4.9% obese by BMI. Compared with normal weight, underweight was associated with higher risk of severe exacerbation (HR 2.05, 95% CI: 1.27–3.32) and mortality (HR 2.94, 95% CI: 1.50–5.77), whereas overweight showed lower mortality risk (HR 0.24, 95% CI 0.09–0.61). Based on adiposity–muscularity phenotyping, 21.9% were lean-robust, 28.4% wasting, 20.1% sarcopenic obesity, and 29.6% obese-robust. Using lean-robust as reference, wasting and sarcopenic obesity were associated with increased risks of severe exacerbation (HR 1.96, 95% CI:1.26-3.06; HR 1.81, 95% CI:1.12-2.94) and mortality (HR 12.6, 95% CI: 3.01-53.2; HR 15.2, 95% CI: 3.57-64.61). The obese-robust demonstrated comparable risks of severe exacerbation and mortality to the lean-robust group. Conclusion BMI alone inadequately stratifies prognosis in COPD. Phenotyping based on adiposity and muscularity identifies high-risk subgroups more precisely. The apparent obesity paradox may reflect preserved muscularity rather than adiposity itself, underscoring the importance of body composition assessment in clinical practice.
  • Ming Yang Presenter Hong Kong
    Background: Paediatric obstructive sleep apnoea (OSA) is a prevalent disorder characterised by recurrent upper airway obstruction, resulting in hypoxia and sleep fragmentation. Epidemiological evidence links Interleukin (IL)-17A to OSA. However, few studies have examined both local and systemic IL 17A profiles to identify meaningful inflammatory phenotypes, and the relationship between these phenotypes and polysomnographic indices remains unclear. Methods: Children aged 5-12 years underwent clinical assessment and polysomnography. Plasma and nasal epithelial lining fluid (NELF) IL-17A were measured by cytometric bead array, with K-means clustering of standardised values identifying inflammatory phenotypes. Across clusters, differences in obstructive apnoea-hypopnoea index (OAHI), oxygen desaturation index (ODI), and arousal index (ARI) were evaluated using Kruskal-Wallis tests with Dunn's post-hoc tests and confounder-adjusted generalised linear models (GLMs). Results: One hundred and six children were recruited, with plasma and NELF collected. Three distinct IL-17A inflammatory phenotypes were identified as high-IL-17A (n=59), low-IL-17A (n=22), and discordant-IL-17A profiles (n=25) (Figure 1). OAHI (p=0.014) and ARI (p=0.002) differed significantly across clusters, whereas ODI (p=0.837) showed no significant differences. Post-hoc test showed significantly higher OAHI (median (Q1-Q3): 3.23 (0.60-17.12) vs. 0.63 (0.22-2.06), adjusted p=0.022) and ARI (13.70 (9.21-25.63) vs. 8.79 (7.15-10.76), adjusted p=0.003) in the high-IL-17A cluster than those in the low-IL-17A cluster. GLMs showed that both low IL 17A and discordant-IL-17A clusters had significantly lower OAHI than the high IL 17A cluster (low: β=-0.692, 95%CI(-1.280,-0.105), p=0.023; discordant: β=-0.664, 95%CI(-1.223,-0.104), p=0.022), with the same pattern for ARI (low: β=-0.338, 95%CI(-0.604,-0.071), p=0.015; discordant: β=-0.294, 95%CI(-0.548,-0.041), p=0.025), while no significant differences for ODI. Conclusions: Clustering IL-17A from plasma and NELF revealed a distinct inflammatory phenotype with more respiratory events and fragmented sleep. These findings support IL-17A as a biomarker for identifying children with a distinct pattern of specific OSA-related features.
  • Scott J. Denstaedt Presenter United States
  • Rachel Kohn Presenter United States
Function Room 8, Ground Mezzanine Floor
12:30
16:30

22 November 2026, Sunday

Time Session
09:00
10:30
Andrea Ban Chairperson Malaysia
Ballroom 1, Lower Ground Floor
11:00
12:00
Chinatsu Nishida Chairperson Japan
Nurhayati Mohd Marzuki Chairperson Malaysia
  • Jun-Pyo Myong Speaker Republic of Korea
    "Floods are the most frequent natural disaster worldwide, yet their respiratory health consequences remain comparatively under-recognised. Unlike drowning and traumatic injury, many respiratory effects emerge after floodwaters recede and arise through multiple, interacting pathways. This presentation conceptualises flooding as a sequence of respiratory exposures involving contaminated floodwater, displacement and shelter crowding, water-damaged housing, restoration and cleanup work, and disruption of ongoing healthcare. Growing epidemiological evidence indicates that the respiratory burden may extend well beyond the emergency phase. In a recent study of more than 300 million hospitalisations across 747 communities in eight countries and territories, flood exposure was associated with a cumulative relative risk of 1.30 (95% CI 1.13–1.49) for respiratory hospitalisation, with a delayed, inverted U-shaped lag-response and increased risk persisting for up to 210 days. Following the 2011 Great East Japan earthquake and tsunami, pneumonia hospitalisations increased 5.7-fold, although only 3.6% of post-disaster pneumonia cases were associated with near-drowning. Shelter crowding further increased the incidence of acute respiratory infection. The recovery environment creates additional and potentially modifiable exposures. Flood-damaged housing is associated with persistent dampness and mould, while demolition and restoration work can generate substantial exposure to particulate matter, endotoxin, and fungal glucans. Flood-related infections also remain clinically relevant; historical Korean leptospirosis outbreaks following floods and heavy rainfall demonstrate the interaction between environmental exposure, agricultural work, and severe pulmonary manifestations. Importantly, effect estimates vary across settings, reflecting differences in flood characteristics, housing, population vulnerability, exposure assessment, healthcare access, and recovery conditions. Comparative evidence regarding the effectiveness of post-flood respiratory interventions remains limited. For the Asia-Pacific region, priorities include standardised flood-exposure assessment, longitudinal respiratory surveillance, evaluation of housing and bioaerosol exposures, protection of cleanup workers, continuity of chronic respiratory and tuberculosis care, and rigorous evaluation of preventive interventions. Respiratory health should therefore be incorporated into flood preparedness and recovery well beyond the immediate disaster response. Keywords: flooding; respiratory health; dampness and mould; occupational exposure; disaster preparedness; Asia-Pacific"
  • Kang Mo Gu Speaker Republic of Korea
    Title: Wildfire and Respiratory Health Abstract Wildfires are becoming larger, longer and more frequent, and the Asia-Pacific region is among the areas where wildfire-derived PM2.5 is rising fastest. Landscape-fire air pollution already accounts for an estimated 1.5 million deaths a year, 220,000 of them respiratory, and is projected to grow with each increment of warming. This lecture summarises what wildfire smoke does to the respiratory system and what clinicians can do about it. Wildfire PM2.5 is not urban PM2.5. It is finer, more oxidative and more pro-inflammatory, and it arrives as short, extreme peaks rather than a steady background. Gram for gram, it carries greater macrophage toxicity than urban particulate matter, and oxidative stress is the common pathway of airway injury. Epidemiological evidence is consistent in direction across more than 30 studies of asthma and COPD, although effect sizes vary with how exposure is defined and how vulnerable the population is. Per microgram, smoke PM2.5 increases asthma emergency visits several-fold more than non-smoke PM2.5, and recent large cohorts show the same pattern for long-term exposure, including a 4.6-fold higher per-microgram mortality hazard among older patients with lung cancer. Korean data from the 2017 Samcheok and 2023 Gangneung fires show that respiratory healthcare use rises during the fire, remains elevated for weeks after containment, and is highest in young children — even after an 8-hour fire. The lecture closes with practical responses: identifying high-risk patients, preparing smoke action plans before the season, protecting patients during and after the episode, and strengthening health-system preparedness as wildfire seasons lengthen.
  • Duminda Yasaratne Speaker Sri Lanka
    Climate change is rapidly emerging as one of the defining threats to respiratory health in the 21st century. Rising temperatures, heatwaves, changing aeroallergen patterns and increasing air pollution are altering the epidemiology and severity of respiratory diseases worldwide. These impacts are particularly important for vulnerable populations with asthma, COPD, respiratory infections and chronic lung diseases. The Asia-Pacific region is at the forefront of this challenge. Rapid urbanisation, population density, biomass and fossil-fuel dependence, transboundary air pollution, extreme weather events and climate-sensitive infectious diseases create a complex and interconnected respiratory health burden, influencing both acute respiratory events and long-term lung health. This lecture will explore the global evidence linking climate change with respiratory disease, while highlighting emerging threats and opportunities across the Asia-Pacific region. It will examine the intersection of climate change, air pollution and health inequities, and consider the implications for clinical practice, respiratory services and public health. The session will emphasize the pivotal role of respiratory specialists in climate advocacy, adaptation, prevention and mitigation, and building climate-resilient respiratory health systems.
  • Q&A
Ballroom 2, Lower Ground Floor
12:00
13:00
Azza Omar Chairperson Malaysia
  • Naoya Tanabe Speaker Japan
    Sarcopenia is an important extrapulmonary manifestation of chronic obstructive pulmonary disease (COPD), contributing to reduced physical function and adverse clinical outcomes. Updated Asian Working Group for Sarcopenia (AWGS) 2025 criteria provide a framework for its assessment. Chest computed tomography (CT) enables evaluation of skeletal muscle quantity and quality, offering additional prognostic information. Particularly, reduced erector spinae muscle density, reflecting intramuscular fat accumulation, is associated with loss of health-related independence, in patients with normal body weight. Recent studies have also demonstrated an association between airway mucus plugging and sarcopenia in COPD. Greater mucus plug burden is associated with reduced exercise capacity, skeletal muscle mass, and fat mass, suggesting potential interactions between pulmonary and systemic impairment. These findings highlight the importance of comprehensive assessment beyond airflow limitation. Early identification of sarcopenia and integrated interventions targeting physical activity, nutrition, and respiratory health may improve long-term outcomes in COPD.
  • Pui Ching Shirley Ngai Speaker Hong Kong
    Chronic obstructive pulmonary disease (COPD) is frequently complicated by sarcopenia, a debilitating condition characterized by the accelerated loss of skeletal muscle mass and functional capacity. Compared with their healthy counterparts, individuals with COPD have a higher prevalence of developing sarcopenia. This disproportionate burden is driven by distinct, disease-specific biological mechanisms. Notably, COPD induces a structural muscle fiber shift from fatigue-resistant oxidative fibers (Type I) to force-predominant glycolytic fibers (Type II). This metabolic shift is fundamentally compounded by decreased capillarization and prominent intramuscular fat infiltration, which collectively compromise oxidative capacity and accelerate functional decline. Previous studies suggest that targeted nutritional intervention is critical in managing this complex phenotype, yet standard dietary guidelines routinely fall short. This presentation summarises the clinical recommendations and discusses how the nutritional supplementation would help and support the management for people with COPD.
  • Soo Chin Chan Speaker Malaysia
    This presentation explores sarcopenia in COPD from a rehabilitation perspective, focusing on how COPD affects skeletal muscle and how exercise training can modify these changes. It highlights the complementary roles of resistance and endurance training, before considering how pulmonary rehabilitation translates physiological improvements into better function and participation. The key message is that exercise targets the muscle, while rehabilitation helps translate these gains into what matters to the patient.
  • Q&A
Ballroom 3, Lower Ground Floor